Full description Finding a path to market for laboratory successes can be a complex process. A key challenge is producing potentially valuable compounds arising from biotechnology research (“biotechnology products”) in quantities large enough to support pre-commercial trials. The Australian Government committed $35 million through the National Collaborative Research Infrastructure Strategy (NCRIS) to enhance Australia’s capacity to produce biotechnology products in pre-commercial quantities in three distinct areas: * recombinant proteins, for use as potential therapeutics; * human cells, for transplantation or clinical activity involving human subjects; and * biofuels. NCRIS funding expands the national capacity to produce recombinant proteins, human cells and biofuels.
program
NCRIS Capability - Biotechnology Products
Provided by NCRIS